Durante uma infecção o número de linfócitos T aumenta dramaticamente. A fase de expansão clonal é seguida pela redução do nível de células T ativadas que depende, em parte, de um processo de morte celular induzida por ativação (AICD). Nosso grupo mostrou que APCs quando são estimuladas com LPS, um agonista de TLR4, produzem PGE2, que inibe a AICD de linfócitos T CD4+ através da supressão da expressão de CD95L (Weinlich et al, 2008). Porém, os efeitos da estimulação direta de TLR nos linfócitos T sobre o processo de AICD foram pouco elucidados. Sendo assim, o projeto tem como objetivo verificar se a estimulação dos diversos TLRs com seus agonistas é capaz de modular a AICD de hibridomas de linfócito T DO11.10. Inicialmente, demonstramos que este hibridoma expressa os TLR1, 2, 3, 4, 5, 6, 7, 9 e 11. Dentre todos os agonistas utilizados somente o Imiquimod, um agonista de TLR7, reduziu a morte celular quando adicionado durante a indução de AICD. O efeito protetor desse agonista foi através da inibição da expressão de CD95L, tanto no nível de mRNA quanto protéico. / During an infection the number of T lymphocytes increases dramatically. The clonal expansion phase is followed by reducing the level of activated T cells that depends, in part, a process of cell death induced by activation (AICD). Our group showed that when APCs are stimulated with LPS, a TLR4 agonist, produce PGE2, which inhibits the AICD of CD4 + T cells by suppressing the expression of CD95L (Weinlich et al, 2008). However, the effects of direct stimulation of TLR on T cells on the process of AICD were little explained. Therefore, the project aims to determine whether the stimulation of different TLRs to their agonist is able to modulate AICD of T lymphocyte hybridoma DO11.10. Initially, we demonstrated that this hybridoma expresses TLR1, 2, 3, 4, 5, 6, 7, 9 and 11. Among all agonists used only imiquimod, a TLR7 agonist, reduced cell death when added during the induction of AICD. The protective effect of this agonist was by inhibiting the expression of CD95L, both at the mRNA and protein.

La mayoría de los ligandos de GPCR que actúan como agonistas, antagonistas o agonistas inversos, se unen al mismo dominio del receptor reconocido por los agonistas endógenos, es decir, el lugar de unión ortostérico. Muchos GPCR poseen sitios alostéricos topográficamente distintos a los ortostéricos. Esto ha llevado a la identificación y estudio de ligandos que actúan como moduladores alostéricos, que pueden regular indirectamente la actividad de los ligandos ortostéricos y/o mediar directamente efectos agonista/antagonista. Este es el caso del híbrido trans-indoloquinolicidina-péptido 28 (IP28) estudiado en la primera parte de esta Tesis Doctoral. Este compuesto es un modulador alostérico de los receptores de dopamina D1, actuando como ligando ortostérico para los receptores D2, D3, D4 y D5 de dopamina; disminuyendo la afinidad del ligando y la potencia de los receptores, preservando al mismo tiempo la eficacia de los mismos y actuando como un agonista débil por si mismo. A pesar de una cierta resistencia inicial por parte de la comunidad científica, la existencia de heterómeros entre diversos receptores de neurotransmisores y neuromoduladores es, hoy por hoy, un hecho aceptado. La heteromerización implica cambios en la forma de entender la neurotransmisión. Así, los receptores no pueden considerarse como una única unidad funcional, sino como agregados multimoleculares localizados en el plano de la membrana plasmática. Bajo esta idea, en la segunda parte de esta tesis se demostró que los receptores de dopamina D2S, D4.2 y D4.4, pero no la variante D4.7 asociada con el trastorno de déficit de atención e hiperactividad (ADHD), forman heterómeros funcionales en células transfectadas y en cerebro de ratón. La coestimulación de los receptores D2S y D4 en el heterómero D2S-D4 tiene un efecto sinérgico en la señalización, hecho que no ocurre en células que expresaban la variante D4.7 o en el estriado de ratones mutados (knock-in) portadores de la variante de 7 repeticiones (D4.7) en el tercer bucle intracelular del receptor D4 de dopamina. Estos resultados indican una diferencia funcional de la variante D4.7 del receptor D4 respecto a las variantes D4.2 y D4.4, la cual puede tener implicaciones importantes para la comprensión de la patogénesis de ADHD. Otra particularidad del receptor de dopamina D4 es que es el único receptor dopaminérgico en la glándula pineal de rata sin que se conozca cual es su función a pesar de que se expresa de manera circadiana. Por tanto, la glándula pineal de rata es una región del cerebro con gran interés para investigar las características del receptor D4. Dado que la glándula pineal está bajo el control de los receptores α1B y β1 adrenérgicos, de cuya activación depende la regulación del ritmo circadiano y la síntesis y liberación de serotonina y melatonina, una posibilidad es que los receptores de dopamina D4, que en animales no presenta formas polimórficas, puedan modular la función de los receptores adrenérgicos de la glándula pineal mediante un proceso de heteromerización. Basado en esta hipótesis, en la tercera parte experimental de esta tesis se ha identificado un nuevo mecanismo que describe como la dopamina regula la función de los receptores adrenérgicos durante el ritmo circadiano. Utilizando diversas técnicas experimentales se ha puesto de manifiesto que: 1) los receptores D4 de dopamina forman heterómeros con receptores adrenérgicos α1B y β1 en células transfectadas y en la glándula pineal 2) los heterómeros α1B-D4 y β1-D4 permiten la modulación inducida por agonistas y antagonistas del receptor D4 de la activación de MAPK y Akt mediada por agonistas de los receptores adrenérgicos en células transfectadas y en la glándula pineal 3) la síntesis y la liberación de serotonina y melanina, promovida por la estimulación de los receptores adrenérgicos en la glándula pineal, está controlada por el receptor D4 a través de la activación de los heterómeros α1B-D4 y β1-D4, y 4) la modulación de los heterómeros a través de los receptores D4 depende de los ciclos circadianos de día/noche. La búsqueda de ligandos específicos para receptores que puedan acoplarse a un sistema de transferencia de energía es de gran interés, ya que las técnicas de BRET y FRET no son aplicables a tejidos ex vivo. Debido a ello, en la cuarta y última parte de esta Tesis se ha querido contribuir al desarrollo de ligandos para receptores de dopamina útiles para detectar heterómeros que contengan estos receptores. Para ello se ha desarrollado y caracterizado ergopéptidos biotinilados como herramientas para el estudio de heterómeros que contengan receptores de dopamina. Así pues, se ha utilizado una quimioteca de ergopéptidos unidos a biotina mediante un espaciador apropiado que conservan sus propiedades como ligandos de receptores de dopamina, identificándose el compuesto 13 como un agonista de elevada afinidad para los receptores D1, D2 y D3 de dopamina y convirtiéndose así en una herramienta útil para estudiar heterómeros que contengan estos receptores. / In the first part of this thesis, we obtained a trans-indoloquinolizidine-peptide hybrid (IP28) obtained by a combinatorial approach, behaved as an orthosteric ligand of all dopamine D2- like receptors (D2, D3, and D4) and dopamine D5 receptors, but as a negative allosteric modulator of agonist and antagonist binding to striatal dopamine D1 receptors. Indoloquinolizidine-peptide 28 induced a concentration-dependent hyperbolic increase in the antagonist apparent equilibrium dissociation constant values and altered the dissociation kinetics of dopamine D1 receptor antagonists. In the second part of this thesis, we show that whereas the most frequent 4-repeat (D4.4) and the 2-repeat (D4.2) variants form functional heteromers with the short isoform of the dopamine D2 receptor (D2S), the 7-repeat risk allele (D4.7) does not. D2 receptor activation in the D2S–D4 receptor heteromer potentiates D4 receptor- mediated MAPK signaling in transfected cells and in the striatum, which did not occur in cells expressing D4.7 or in the striatum of knockin mutant mice carrying the 7 repeats of the human D4.7 in the third intracellular loop of the D4 receptor. Using the same receptor, le dopamine D4R, in the third part of this thesis, we describe that the production of both melatonin and serotonin by the pineal gland is regulated by a circadian-related heteromerization of adrenergic and dopamine D4 receptors. Through α1B-D4 and β1-D4 receptor heteromers dopamine inhibits adrenergic receptor signaling and blocks the synthesis of melatonin induced by adrenergic receptor ligands. And this inhibition was not observed at hours of the day when D4 was not expressed. Finally, in the last part of this thesis, we made the systematic derivatization of two ergopeptides with different peptide-based spacers and we realized their evaluation by radioligand binding assays. Selected spacer-containing ergopeptides with minimal biological alteration and a proper anchoring point were further derivatized with a biotin reporter. Detailed characterization studies identified 13 as a biotin ergopeptide maintaining high affinity and agonist behavior at dopamine receptors, being a useful tool for the study of heteromers involving D1R, D2R, or D3R.

The amphibian species Xenopus laevis, along with mouse and chicken is a very important model system, used widely to dissect the molecular intricacies of various aspects of vertebrate development. Study with Xenopus has clear advantages in terms of various technical considerations including the ease of handling early stage of embryos and due to the remarkable documentation of several early molecular events during development. The concept of inductive interactions between various cell types during early development was first revealed by the studies performed in Xenopus, and among the various factors proposed for mesoderm induction, the members of transforming growth factor-β (TGF- β) superfamily have been considered to be the most probable candidates. About forty different members of the TGF-β superfamily have been cloned and characterized from various organisms. The superfamily members like activins and BMPs have been studied extensively with respect to their functional role during development. While BMPs were assigned as candidates for inducing ventral mesoderm, activins oppose the role of BMPs by inducing dorsal mesoderm. Studies that helped in delineating their roles were performed using three approaches that utilized the ligands, receptors or down stream signaling components (Smads). All the three components were studied with respect to their endogenous expression pattern and effects of ectopic expressions of the wild type or dominant negative mutants. These approaches led to the accumulation of evidences supporting the importance of these signaling molecules. All the above mentioned studies were only possible due to the cloning and characterization of cDNAs of the various proteins involved in the signaling pathway including the ligands. TGF-β2 and 5 are the two isoforms of TGF-β cloned from the amphibian system. We have earlier cloned and characterized the promoter for TGF-β5 gene, which suggested possible regulation of this factor by tissue specific transcription factors. Messenger RNA in situ hybridization analysis to study the TGF-β5-expression pattern during Xenopus development, showed spatial and temporal expression pattern. The expression was confined to specific regions that include notochord, somites, and tail bud among others, in the various stages analyzed. This suggested a possible role for TGF-β5 in organogenesis during the amphibian development. To better understand the role of TGF-β in Xenopus development, studies to examine the specific receptor expression pattern for this growth factor is very essential. With the lack of any reports on cloning of TGF-β receptors from this system, the aim of the present study was to isolate and characterize the receptors for TGF-β from Xenopus laevis. PCR cloning using degenerate primers based on the conserved kinase domains of this class of receptors, coupled to library screenings enabled the identification of two novel receptor cDNAs of the TGF-β receptor superfamily. Characterization of the isolated cDNAs suggested that one of them codes for a type II receptor for TGF-β. Further the cDNAs were found to be ubiquitously expressed during development, as judged by RT-PCR analysis. The cloned cDNAs can now be employed as tools, to study the expression pattern by means of mRNA in situ hybridization, on the various developmental stage embryos and to perform studies using antisense and dominant negative mRNA injection experiments in vivo. Such studies will greatly assist in delineating the role of TGF-β ligands and receptors during amphibian development.

Durante uma infecção o número de linfócitos T aumenta dramaticamente. A fase de expansão clonal é seguida pela redução do nível de células T ativadas que depende, em parte, de um processo de morte celular induzida por ativação (AICD). Nosso grupo mostrou que APCs quando são estimuladas com LPS, um agonista de TLR4, produzem PGE2, que inibe a AICD de linfócitos T CD4+ através da supressão da expressão de CD95L (Weinlich et al, 2008). Porém, os efeitos da estimulação direta de TLR nos linfócitos T sobre o processo de AICD foram pouco elucidados. Sendo assim, o projeto tem como objetivo verificar se a estimulação dos diversos TLRs com seus agonistas é capaz de modular a AICD de hibridomas de linfócito T DO11.10. Inicialmente, demonstramos que este hibridoma expressa os TLR1, 2, 3, 4, 5, 6, 7, 9 e 11. Dentre todos os agonistas utilizados somente o Imiquimod, um agonista de TLR7, reduziu a morte celular quando adicionado durante a indução de AICD. O efeito protetor desse agonista foi através da inibição da expressão de CD95L, tanto no nível de mRNA quanto protéico. / During an infection the number of T lymphocytes increases dramatically. The clonal expansion phase is followed by reducing the level of activated T cells that depends, in part, a process of cell death induced by activation (AICD). Our group showed that when APCs are stimulated with LPS, a TLR4 agonist, produce PGE2, which inhibits the AICD of CD4 + T cells by suppressing the expression of CD95L (Weinlich et al, 2008). However, the effects of direct stimulation of TLR on T cells on the process of AICD were little explained. Therefore, the project aims to determine whether the stimulation of different TLRs to their agonist is able to modulate AICD of T lymphocyte hybridoma DO11.10. Initially, we demonstrated that this hybridoma expresses TLR1, 2, 3, 4, 5, 6, 7, 9 and 11. Among all agonists used only imiquimod, a TLR7 agonist, reduced cell death when added during the induction of AICD. The protective effect of this agonist was by inhibiting the expression of CD95L, both at the mRNA and protein.

Recentemente, a expressão gênica dos receptores TLR foi encontrada em diversos tipos de células tumorais. A sua participação na biologia do câncer é controversa já que foram descritas ações pró e anti-tumorais após a ativação de sua sinalização. Na Leucemia Mielóide Crônica (LMC) nada se tem demonstrado. BCR-ABL é uma oncoproteína quimérica cujo sítio tirosina quinasa constitutivamente ativado promove inúmeras vias de sinalizações que desencadeia a transformação celular. Este trabalho se inicia com a hipótese de existir uma relação entre o oncogene BCR-ABL e a expressão dos receptores TLRs. Nós verificamos em células murinas TonB210.1 com expressão de BCR-ABL induzível por doxiciclina que Tlr1 e Tlr2 tem sua expressão gênica relativa aumentada na presença da oncoproteína. A regulação positiva de Tlr1 é dependente da ação tirosina quinasa de BCR-ABL. Também mostramos que as vias p38 e JNK estão reprimindo a expressão de Tlr1 induzida por BCR-ABL enquanto que a via ERK é utilizada pelo BCR-ABL para promovê-la. Por outro lado, observamos que a ligação de TLR1/TLR2 com seu agonista sintético Pam3CSK4 em células TonB210.1 BCR-ABL positivas induz um aumento da produção de IL-6 e leva ao aumento da resistência a morte quando induzida pelas drogas Ara-C e VP16. Em conclusão, estes resultados indicam que BCR-ABL esta regulando a expressão gênica de alguns TLRs. Por tanto esses dados contribuem para a compreensão sobre o comportamento de células tumorais BCR-ABL positivas em um contexto de infecção e por conseqüência, dão margem ao estudo de novos alvos de fator de risco para a LMC. / Recently, the gene expression of TLR receptors have been described in several kinds of tumour cells. Its participation in cancer biology is controversial because roles were already been described in pro and anti-tumoral activities after their signaling activation. In Chronic Myeloid Leukemia (CML) there are no published data. BCR-ABL is a quimeric protein and its tyrosine-kinase site is activated constitutively. Thus, many signaling pathways are activated and several cell processes are altered thereby resulting in cellular transformation. This work has started with the hypothesis that a putative relationship between the oncogene BCR-ABL and the expression of TLR receptors could exists. We verified in murine cells TonB210.1 BCR-ABL expression inducible by doxycicline that Tlr1 and Tlr2 have their relative gene expression up-regulated in the presence of the oncoprotein. Therefore the Tlr1 regulation is dependent of BCR-ABL tyrosine kinase action. Using MAPK inhibitors we showed that p38 and JNK pathways are suppressing the TLR1 induction by BCR-ABL while ERK pathway is used by the oncoprotein for promote it. On the other hand, we observed in TonB210.1 BCR-ABL positive cells that the binding of TLR1/TLR2 heterodimer to their synthetic agonist Pam3CSK4 induced an increased production of IL-6 and when these cells were induced by Ara-C and VP-16 drugs the apoptosis resistance increased. In conclusion, these results indicate that the oncoprotein regulates the gene expression of some TLRs. Therefore, this fact gives us data about the behavior of BCR-ABL positive tumor cells in the context of infection and in consequence the study of new risk factor targets for CML.

Le VIP (ou vasoactive intestinal peptide) est un neuropeptide actif au niveau du syst¨¨me nerveux central et p¨¦riph¨¦rique (syst¨¨mes cardiovasculaire, respiratoire, tractus gastro-intestinal¡­). Il agit sur ces tissus cibles par interaction avec les r¨¦cepteurs VPAC1 et VPAC2, pour lesquels il poss¨¨de une haute affinit¨¦. Ces r¨¦cepteurs appartiennent ¨¤ la classe II des r¨¦cepteurs ¨¤ 7 h¨¦lices transmembranaires coupl¨¦s aux prot¨¦ines G, distincte de celle des r¨¦cepteurs apparent¨¦s ¨¤ la rhodopsine. En r¨¦ponse au VIP, ils stimulent pr¨¦f¨¦rentiellement l'ad¨¦nylate cyclase. Seul le r¨¦cepteur VPAC1 est capable, lorsqu'il est exprim¨¦ ¨¤ haute concentration, d¡¯augmenter les concentrations de calcium intracellulaire :G*i participe ¨¤ cette interaction. L'exposition des deux r¨¦cepteurs au VIP n'aboutit pas seulement ¨¤ leur activation :elle induit une succession de m¨¦canismes cellulaires intrins¨¨ques responsables d'une diminution de la capacit¨¦ du r¨¦cepteur ¨¤ r¨¦pondre ¨¤ un agoniste :la d¨¦sensibilisation. <p>Diff¨¦rents processus peuvent contribuer ¨¤ la d¨¦sensibilisation d¡¯un r¨¦cepteur :le d¨¦couplage du r¨¦cepteur de la prot¨¦ine G, la s¨¦questration du r¨¦cepteur, ou encore leur "down regulation", r¨¦sultat ¨¤ plus long terme de la perte d'une partie du pool total de r¨¦cepteurs. Les m¨¦canismes impliqu¨¦s d¨¦pendent du r¨¦cepteur consid¨¦r¨¦ et de l'¨¦quipement prot¨¦ique de la cellule. <p>Il a ¨¦t¨¦ r¨¦cemment montr¨¦ que le r¨¦cepteur VPAC1 humain ¨¦tait phosphoryl¨¦ (en position S447) en r¨¦ponse ¨¤ l¡¯agoniste, que la ¦Â-arrestine ¨¦tait transloqu¨¦e ¨¤ la membrane plasmique et que l¡¯internalisation qui s¡¯en suivait induisait un ph¨¦nom¨¨ne dynamine-d¨¦pendant. Aucune information plus pr¨¦cise n¡¯est r¨¦f¨¦r¨¦e dans la litt¨¦rature. <p>Ce travail de th¨¨se a donc consist¨¦ en une ¨¦tude plus approfondie de la phosphorylation, l¡¯internalisation et la r¨¦cup¨¦ration du r¨¦cepteur VPAC1 humain.<p><p>Dans un premier temps, nous nous sommes consacr¨¦ ¨¤ l¡¯¨¦laboration d¡¯un anticorps monoclonal sp¨¦cifique anti-r¨¦cepteur afin de visualiser le r¨¦cepteur. Nous avons eu recours ¨¤ l¡¯immunisation g¨¦n¨¦tique qui consiste ¨¤ injecter l¡¯antig¨¨ne sous forme d¡¯ADN. <p>Une majorit¨¦ des souris immunis¨¦es ont produit des anticorps. L¡¯une d¡¯entre-elle a permis de g¨¦n¨¦rer un anticorps monoclonal, lequel a ¨¦t¨¦ compl¨¨tement caract¨¦ris¨¦ :les r¨¦sultats obtenus par FACS montrent qu¡¯il est sp¨¦cifique, s¨¦lectif et que son ¨¦pitope est localis¨¦e au sein de l¡¯extr¨¦mit¨¦ amino-terminale du r¨¦cepteur (figure 1). Il n¡¯interf¨¨rent pas avec la liaison du ligand et ne modifie en rien l¡¯activation du r¨¦cepteur par celui-ci. Cet anticorps monoclonal ne permet pas de d¨¦tecter le r¨¦cepteur par Western Blott, mais est capable de l¡¯immunopr¨¦cipiter. <p><p>Dans un second temps, nous avons abord¨¦ l¡¯¨¦tude de la phosphorylation, de l¡¯internalisation et du trafficking du r¨¦cepteur VPAC1 humain.<p> / Doctorat en sciences médicales / info:eu-repo/semantics/nonPublished

Indiana University-Purdue University Indianapolis (IUPUI) / Neuropathic pain is a serious health problem that greatly impairs quality of life. The International Association for the Study of Pain (IASP) defines neuropathic pain as ‘pain arising as a direct consequence of a lesion or disease affecting the nervous system’. It is important to note that with neuropathy the chronic pain is not a symptom of injury, but rather the pain is itself a disease process. Novel interactions between the nervous system and elements of the immune system may be key facets to a chronic disease state. One of particular note is the recent finding supporting an interaction between an immune response protein high mobility group box 1 (HMGB1) and Toll like receptor 4 (TLR4). HMGB1 is an endogenous ligand for TLR4 that influences the induction of cytokines in many non-neuronal cells. After tissue damage or injury, HMGB1 may function as a neuromodulatory cytokine and influence the production of pro-nociceptive mediators altering the state of sensory neurons. Very little is known about the HMGB1-TLR4 interaction in sensory neurons and whether chronic changes in endogenous HMGB1 signaling influence the establishment of neuropathic pain. This thesis aims to determine whether a physiologically relevant neuroimmune interaction involving endogenous HMGB1 and TLR4 in the dorsal root ganglia is altered following a tibial nerve injury model of neuropathic pain. I hypothesized that sensitization of sensory neurons following a peripheral nerve injury is dependent on endogenous HMGB1 and TLR4. The studies presented here demonstrate that HMGB1 undergoes subcellular redistribution from the nucleus to the cytoplasm in primary afferent neurons following peripheral nerve injury. Further, the presence of extracellular HMGB1 may directly contribute to peripheral sensitization and injury-induced tactile hyperalgesia. Though thought to be important as a pivotal receptor for HMGB1 activation, neuronal protein expression of TLR4 does not appear to influence the effects of HMGB1-dependent behavioral changes following peripheral nerve injury. Taken together, these findings suggest that extracellular HMGB1 may serve as an important endogenous cytokine that contributes to ongoing pain hypersensitivity in a rodent model of neuropathic pain.

Cancer immunotherapies utilize the capabilities of the immune system to efficiently target malignant cells. In recent years, chimeric antigen receptor (CAR) equipped T cells showed promising results against B cell lymphomas. Autologous CAR-T cells require patientspecific manufacturing and thus extensive production facilities, resulting in high priced therapies. Along with potentially severe side effects, these are the major drawbacks of CAR-T cells therapies. Natural Killer (NK) cells pose an alternative for CAR equipped immune cells. Since NK cells can be safely transferred from healthy donors to cancer patients, they present a suitable platform for an allogeneic “off-the-shelf” immunotherapy. However, administration of activated NK cells in cancer therapy has until now shown poor anti-cancer responses, especially in solid tumors. Genetic modifications such as CARs promise to enhance recognition of tumor cells, thereby increasing anti-tumor effects and improving clinical efficacy. Although the cell biology of T and NK cells deviates in many aspects, the development of CAR-NK cells frequently follows within the footsteps of CART cells, meaning that T cell technologies are simply adopted to NK cells. In this review, we underline the unique properties of NK cells and their potential in CAR therapies. First, we summarize the characteristics of NK cell biology with a focus on signaling, a fine-tuned interaction of activating and inhibitory receptors. We then discuss why tailored NK cellspecific CAR designs promise superior efficacy compared to designs developed for T cells. We summarize current findings and developments in the CAR-NK landscape: different CAR formats and modifications to optimize signaling, to target a broader pool of antigens or to increase in vivo persistence. Finally, we address challenges beyond NK cell engineering, including expansion and manufacturing, that need to be addressed to pave the way for CAR-NK therapies from the bench to the clinics.

Indiana University-Purdue University Indianapolis (IUPUI) / In response to different environmental stresses, phosphorylation of eIF2 (eIF2P) represses global translation coincident with preferential translation of ATF4. ATF4 is a transcriptional activator of the integrated stress response, a program of gene expression involved in metabolism, nutrient uptake, anti-oxidation, and the activation of additional transcription factors, such as CHOP/GADD153, that can induce apoptosis. Although eIF2P elicits translational control in response to many different stress arrangements, there are selected stresses, such as exposure to UV irradiation, that do not increase ATF4 expression despite robust eIF2P. In this study we addressed the underlying mechanism for variable expression of ATF4 in response to eIF2P during different stress conditions and the biological significance of omission of enhanced ATF4 function. We show that in addition to translational control, ATF4 expression is subject to transcriptional regulation. Stress conditions such as endoplasmic reticulum stress induce both transcription and translation of ATF4, which together enhance expression of ATF4 and its target genes in response to eIF2P. By contrast, UV irradiation represses ATF4 transcription, which diminishes ATF4 mRNA available for translation during eIF2∼P. eIF2P enhances cell survival in response to UV irradiation. However, forced expression of ATF4 and its target gene CHOP leads to increased sensitivity to UV irradiation. In this study, we also show that C/EBPβ is a transcriptional repressor of ATF4 during UV stress. C/EBPβ binds to critical elements in the ATF4 promoter resulting in its transcriptional repression. The LIP isoform of C/EBPβ, but not the LAP version is regulated following UV exposure and directly represses ATF4 transcription. Loss of the LIP isoform results in increased ATF4 mRNA levels in response to UV irradiation, and subsequent recovery of ATF4 translation, leading to enhanced expression of its target genes. Together these results illustrate how eIF2P and translational control, combined with transcription factors regulated by alternative signaling pathways, can direct programs of gene expression that are specifically tailored to each environmental stress.

Indiana University-Purdue University Indianapolis (IUPUI) / Murine double minute (Mdm2) is a highly modified and multi-faceted protein that is overexpressed in numerous human malignancies. It engages in many cellular activities and is essential for development since deletion of mdm2 is lethal in early stages of embryonic development. The most studied function of Mdm2 is as a negative regulator of the tumor suppressor protein p53. Mdm2 achieves this regulation by binding to p53 and inhibiting p53 transcriptional activity. Mdm2 also functions as an E3 ubiquitin ligase that signals p53 for destruction by the proteasome. Interestingly recent evidence has shown that Mdm2 can also function as an E3 neddylating enzyme that can conjugate the ubiquitin-like molecule, nedd8, to p53. This modification results in inhibition of p53 activity, while maintaining p53 protein levels. While the signaling events that regulate Mdm2 E3 ubiquitin ligase activity have been extensively studied, what activates the neddylating activity of Mdm2 has remained elusive. My investigations have centered on understanding whether tyrosine kinase signaling could activate the neddylating activity of Mdm2. I have shown that c-Src, a non-receptor protein tyrosine kinase that is involved in a variety of cellular processes, phosphorylates Mdm2 on tyrosines 281 and 302. This phosphorylation event increases the half-life and neddylating activity of Mdm2 resulting in a neddylation dependent reduction of p53 transcriptional activity. Mdm2 also has many p53-independent cellular functions that are beginning to be linked to its role as an oncogene. There is an emerging role for Mdm2 in tumor metastasis. Metastasis is a process involving tumor cells migrating from a primary site to a distal site and is a major cause of morbidity and mortality in cancer patients. To date, the involvement of Mdm2 in breast cancer metastasis has only been correlative, with no in vivo model to definitively define a role for Mdm2. Here I have shown in vivo that Mdm2 enhances breast to lung metastasis through the up regulation of multiple angiogenic factors, including HIF-1 alpha and VEGF. Taken together my data provide novel insights into important p53-dependent and independent functions of Mdm2 that represent potential new avenues for therapeutic intervention.